Loading patent…
AssigneeBiogen MA Inc.
InventorsBlake PEPINSKY, Laura RUNKEL, Margot BRICKELMAIER, Adrian WHITTY, Paula HOCHMAN
Estimating the term…
An interferon beta polypeptide comprising interferon-beta 1a coupled to a polymer containing a polyalkylene glycol moiety wherein the interferon-beta-1a and the polyalkylene glycol moiety are arranged such that the interferon-beta-1a has an enhanced activity relative to another therapeutic form of interferon beta (interferon-beta-1b) and exhibits no decrease in activity as compared to non-conjugated interferon-beta-1a. The conjugates of the invention are usefully employed in therapeutic as well as non-therapeutic, e.g., diagnostic, applications.
A method of preparing a glycosylated interferon beta-1a molecule coupled to a polyethylene glycol polymer at an N-terminal end of the glycosylated interferon beta-1a molecule comprising steps of:
A method of decreasing stress-induced aggregation of interferon beta-1a, comprising coupling glycosylated interferon-beta-1a having the amino acid sequence of SEQ ID NO:
A subcutaneous unit dosage form filled with a composition comprising a glycosylated interferon-beta-1a having the amino acid sequence set forth in SEQ ID NO:
Dependencies are inferred from the claim text.